Industry

Citing financial pressure from the loss of its patent on Zyprexa, Eli Lilly announced that it will freeze base pay for most of its...

Gary Skala's claim that 14 years of Risperdal caused his diabetes went to trial in New Jersey yesterday in the first personal injury lawsuit...

John Read and Richard Bentall write in the British Journal of Psychiatry about the growing understanding and acceptance of the significant role adverse childhood...

A 2011 whistleblower complaint that was unsealed on January 20 of this year alleges that Forest Pharmaceuticals bribed a principle investigator of the STAR*D...

L. Alan Sroufe, emeritus professor of psychology at the University of Minnesota, writes in the New York Times Sunday Review that there is no...

Mary O'Hagan, an international mental health leader with lived experience, writes on the paradox of increasing legal coercion of psychiatric patients, even as the...

While the DSM-IV recognizes that depressive symptoms are sometimes normal in bereaved individuals, this "Bereavement Exclusion" is targeted for elimination from the DSM-V. However...

With at least 59 lawsuits pending over birth defects allegedly caused by Zoloft, Pfizer moves to consolidate litigation near its headquarters in New York. Read...

The Wall Street Journal reports that Johnson & Johnson's fourth-quarter earnings fell 89% following settlements for misrepresenting the risks and benefits of Risperdal, its...

Canadian sleep researchers, writing in The Lancet, warn that weight gain, lipid and glucose dysregulation, restless leg syndrome, sleep-walking and eating while asleep, and...

Researchers at the University of Massachusetts found that children are more than twice as likely to develop diabetes when treated with antidepressants, and more...

In the wake of the Johnson & Johnson's settlements over its improper marketing of Risperdal, Forbes magazine comments on the company's "vulnerable and now...

Johnson & Johnson has agreed to settle Texas' lawsuit for the company's fraudulent marketing of Risperdal. The is the first time J&J has settled...

The number of "visits" by bipolar patients 18 and older to office-based physicians in the U.S. rose from 3.7 million in 1998 to 7.8...

Because of the increased use of generic drugs, there has been a slowdown in the growth of spending for psychiatric drugs in the United...

In clinical trials, nicotine gum and patches are effective in helping people quit smoking. However, researchers have found that nicotine-replacement therapies do not lower...

Texas' lawsuit against Johnson & Johnson for its off-label marketing of Risperdal, which the state alleges involved fraudulent claims about the drug's safety and...

In order to resolve a civil investigation into the marketing of Risperdal for unapproved uses, Johnson & Johnson will pay more than $1 billion...

In a review of seven clinical trials of duloxetine (Cymbalta), researchers found that the drug-treated patients fell into two groups: 76.7% "responded" to the...

From 1996 to 2007, the number of children ages five to 13 discharged from a psychiatric inpatient unit nearly doubled on a per-capita basis....

Article from Wired magazine in 2010 about Allen Frances, lead editor of the DSM-IV, and his criticism of both the DSM-IV and the upcoming DSM-5. Article →